Bone Biologics Corporation has announced the appointment of Stephen R. La Neve as chief executive officer and president, and Jeffrey Frelick as chief operating officer of the company.
According to a company press release, La Neve previously served as CEO and president of Etex Corporation; president of Becton Dickinson’s Pre-analytical Systems business; president of Medtronic’s Spine and Biologics business; and president of Medtronic Japan. He has also served as senior vice president and executive vice president of Premier and ran the global injection systems business unit for Becton Dickinson. Along with being a consultant for private equity companies in the medical device area, La Neve also serves on the board of directors for SkelRegen LLC and Rapid Pathogen Screening Inc.
Most recently, Frelick was the COO of Life Science Enterprises, and has spent 15 years on Wall Street as a sell-side analyst following the med-tech industry at investment banks such as Canaccord Genuity, ThinkEquity and Lazard, according to a press release. Frelick has also worked at Boston Biomedical Consultants, and has held sales and sales management positions at Becton Dickinson’s Primary Care Diagnostic Division.
“We are pleased to have individuals of the caliber of Steve and Jeff join our company,” Bruce Stroever, Bone Biologics Board Chairman, stated in the release. “We have an exciting technology and now have the full time management to bring this produce to market.”
